Cochrane · systematic review · CD006992
Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control
Vos, RC, van Avendonk, MJP, Jansen, H, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
35
current version
GRADE rated
10
No studies
25
Included studies
NR
No studies 25 · 71.4%Ungraded 0 · 0%Very low 0 · 0%Low 10 · 28.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: sulphonylureas
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | NR | No studies |
Diabetes‐related mortality | no estimate extracted | NR | No studies |
Diabetes‐related morbidity | no estimate extracted | NR | No studies |
Health‐related quality of life | no estimate extracted | NR | No studies |
Patient satisfaction | no estimate extracted | NR | No studies |
Adverse events: a. mild hypoglycaemia (episodes per participant) | no estimate extracted | 8 studies · 239 participants | Low Downgraded: risk of bias, indirectness |
HbA1c, change from baseline (%) | no estimate extracted | 9 studies · 316 participants | Low Downgraded: risk of bias, indirectness |
Summary of findings: metformin
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | NR | No studies |
Diabetes‐related mortality | no estimate extracted | NR | No studies |
Diabetes‐related morbidity | no estimate extracted | NR | No studies |
Health‐related quality of life | no estimate extracted | NR | No studies |
Patient satisfaction | no estimate extracted | NR | No studies |
Adverse events: a. mild hypoglycaemia (episodes per participant) | no estimate extracted | 8 studies · 590 participants | Low Downgraded: risk of bias, indirectness |
HbA1c, change from baseline (%) | no estimate extracted | 9 studies · 698 participants | Low Downgraded: risk of bias, indirectness |
Summary of findings: pioglitazone
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | NR | No studies |
Diabetes‐related mortality | no estimate extracted | NR | No studies |
Diabetes‐related morbidity | no estimate extracted | NR | No studies |
Health‐related quality of life | no estimate extracted | NR | No studies |
Patient satisfaction | no estimate extracted | NR | No studies |
Adverse events: a. mild to moderate hypoglycaemia (episodes per participant) | no estimate extracted | 2 studies · 760 participants | Low Downgraded: risk of bias, imprecision, indirectness |
HbA1c, change from baseline (%) | no estimate extracted | 3 studies · 785 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Summary of findings: alpha‐glucosidase inhibitors
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | NR | No studies |
Diabetes‐related mortality | no estimate extracted | NR | No studies |
Diabetes‐related morbidity | no estimate extracted | NR | No studies |
Health‐related quality of life | no estimate extracted | NR | No studies |
Patient satisfaction | no estimate extracted | NR | No studies |
Adverse events: a. mild hypoglycaemia (% of participants) | no estimate extracted | 4 studies · 583 participants | Low Downgraded: risk of bias, imprecision, indirectness |
HbA1c, change from baseline (%) | no estimate extracted | 3 studies · 448 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Summary of findings: DPP‐4 inhibitors
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | NR | No studies |
Diabetes‐related mortality | no estimate extracted | NR | No studies |
Diabetes‐related morbidity | no estimate extracted | NR | No studies |
Health‐related quality of life | no estimate extracted | NR | No studies |
Patient satisfaction | no estimate extracted | NR | No studies |
Adverse events: a. hypoglycaemia (% of participants) | no estimate extracted | 3 studies · 503 participants | Low Downgraded: risk of bias, imprecision, indirectness |
HbA1c, change from baseline (%) | no estimate extracted | 2 studies · 265 participants | Low Downgraded: risk of bias, imprecision, indirectness |